Tianjin Medical Journal

Tianjin Med J ›› 2015, Vol. 43 ›› Issue (11): 1230-1234.doi: 10.11958/j.issn.0253-9896.2015.11.004

Previous Articles     Next Articles

Update study of GLP-1 receptor agonist in the treatment of non-alcoholic fatty liver disease

LI Chunjun, YU Demin△#br#   

  1. Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University /Ministry of Health Key Laboratory of Hormones and Development, Tianjin 300070, China
  • Received:2015-09-10 Revised:2015-10-25 Published:2015-11-15 Online:2015-11-15
  • Contact: YU Demin E-mail:yudemintij@126.com E-mail:yudemintij@126.com

PDF (PC)

4057

Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases across the world, but there is still no specific treatment for NAFLD. Glucogon-like peptide 1 receptor agonist (GLP-1Ra) is a novel drug for the treatment of type 2 diabetes, based on incretin hormone target. Animal and clinical studies have demonstrated that GLP-1Ra can effectively reduce fat deposit in liver and attenuate hepatic steatosis. Therefore, GLP- 1Ra is a promising therapeutic approach against NAFLD. In this review, we provided an overview of the clinical and basic research evidences and mechanisms in relieving NAFLD.

Key words: glucagon-like peptide 1, incretins, fatty liver, review, glucogon-like peptide 1 receptor agonist, non-alcoholic fatty liver